SHORT-term Effects of GLucagon-like Peptide One on BonE

Launched by ODENSE UNIVERSITY HOSPITAL · Dec 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a hormone called glucagon-like peptide 1 (GLP-1) affects bone health. GLP-1, which is released from the gut after eating, helps regulate blood sugar and hunger but may also play a role in how bones are formed and broken down. The researchers want to find out how different lengths of exposure to GLP-1 influence these processes in healthy adults. They are particularly interested in understanding the effects of short-term (2 hours) versus longer-term (up to 72 hours) exposure to GLP-1 on bone metabolism.

To participate in the study, individuals should be healthy and between the ages of 65 to 74. Certain conditions, such as diabetes, high body weight, recent bone fractures, or pregnancy, would exclude someone from joining. Participants will receive either GLP-1 or a saline solution (a saltwater solution) over 72 hours, using an insulin pump to administer the treatment. The study will involve a few visits for health assessments and will require participants to complete the study procedures and give informed consent. Overall, this research aims to provide insights into how GLP-1 can influence bone health, which could be important for developing treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy
• Exclusion Criteria:
• • Diabetes mellitus including prediabetes (Hb1Ac \>42 mmol/mol at baseline)
• • BMI \> 28 kg/m2
• • Conditions and pharmaceutical treatments that influence bone metabolism (e.g., bone fractures \< 6 months, uncontrolled thyrotoxicosis, and severe renal impairment).
• • Pregnancy
• • Inability to complete all investigations or to provide informed consent